ARCH VENTURE FUND IX, L.P. - LYELL IMMUNOPHARMA -- SCH 13G

Company

Lyell Immunopharma, Inc.

Filed

February 14, 2022

Accession Number

0001072613-22-000148

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →